Invest in Hera Diagnostics

Hera Diagnostics saves lives by delivering cervical cancer screening to the global community

$36,895

reserved of a $50,000 goal
INVESTMENT TERMS
Convertible Note
$13.9M valuation cap
$250, $500, $1K, $10K
Pitch Video
Investor Panel

Highlights

1
Over 300,000 women die annually from cervical cancer even though the disease is easily treatable
2
90% of cervical cancer deaths occur in underserved populations globally
3
Hera will reduce those deaths by delivering high-tech screening to low-tech communities
4
Our device is portable, accurate, affordable, painless and gives real time, point-of-care results

Featured Investor

Our Team

Cervical cancer is a leading cause of death from cancer among women in developing countries. Hera Diagnostics technology was developed to address this crisis through reliable, affordable and immediate screening technology.

Pitch

Overview